MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

target trial emulation

  • Home
  • target trial emulation
Parathyroidectomy Significantly Lowers Cardiovascular Risk in Primary Hyperparathyroidism: Insights from a Population-Wide Target Trial Emulation
Posted inCardiology Diabetes & Endocrinology news

Parathyroidectomy Significantly Lowers Cardiovascular Risk in Primary Hyperparathyroidism: Insights from a Population-Wide Target Trial Emulation

Posted by By MedXY 08/24/2026
This population-wide study demonstrates that parathyroidectomy in primary hyperparathyroidism reduces major adverse cardiovascular events risk, particularly in patients with higher serum calcium levels.
Read More
Ultra-Early Versus Early Vasopressin Initiation After Norepinephrine Escalation in Septic Shock: Insights from a Target Trial Emulation
Posted inCritical Care Internal Medicine news

Ultra-Early Versus Early Vasopressin Initiation After Norepinephrine Escalation in Septic Shock: Insights from a Target Trial Emulation

Posted by By MedXY 08/12/2026
This study emulated a target trial to compare ultra-early (0-3h) versus early (>3-6h) vasopressin initiation after norepinephrine escalation in septic shock, revealing significant mortality and renal therapy benefits with ultra-early use.
Read More
Evaluating the Safety of Same-Day COVID-19 and Influenza Vaccination: Insights from a Large Veterans Affairs Target Trial Emulation
Posted inInfectious Diseases news Public Health

Evaluating the Safety of Same-Day COVID-19 and Influenza Vaccination: Insights from a Large Veterans Affairs Target Trial Emulation

Posted by By MedXY 07/02/2026
A large U.S. Veterans Affairs study found no increased 90-day risk of adverse events after same-day COVID-19 and influenza vaccination compared to influenza vaccination alone, supporting the safety of coadministration with updated COVID-19 formulations.
Read More
Dopamine-Enhancing Therapies in Age-Related Macular Degeneration: Assessing Risk Reduction for Neovascular Conversion
Posted innews Ophthalmology

Dopamine-Enhancing Therapies in Age-Related Macular Degeneration: Assessing Risk Reduction for Neovascular Conversion

Posted by By MedXY 06/25/2026
This study evaluates the association of dopamine-enhancing drugs, especially levodopa, with lowered 3-year risk of progression from non-neovascular to neovascular AMD, offering promising insight into dopaminergic pathways in AMD management.
Read More
Intervention Lowers Long‑Term Hemorrhage Risk in Unruptured Brain AVMs: Evidence From a Nationwide Target‑Trial Emulation
Posted inNeurology news Radiology

Intervention Lowers Long‑Term Hemorrhage Risk in Unruptured Brain AVMs: Evidence From a Nationwide Target‑Trial Emulation

Posted by By MedXY 11/19/2025
A large Chinese registry-based target-trial emulation found interventional therapy for unruptured brain AVMs reduced 5- and 10-year hemorrhage-free survival compared with conservative management, with benefits concentrated in low-grade, compact nidus lesions and driven mainly by microsurgery.
Read More
  • Enhancing Post-Stroke Physical Activity Through Telehealth and Wearable Technology: A Feasibility Randomised Controlled Trial
  • Advancing Dental Education: Repair Versus Replacement of Defective Composite Restorations in Canadian Dental Schools
  • Immunogenicity and Safety of Fractional 17DD Yellow Fever Vaccine Doses in Young Children: Evidence from a Phase 4 Randomised Trial in Uganda and Broader Context
  • Enhancing Prehospital Pediatric Ventilation Quality with Real-Time Feedback Devices: Insights from a Randomized Study
  • Nerandomilast Shows Promise in Slowing Progressive Pulmonary Fibrosis in Autoimmune Disease: Insights from the FIBRONEER-ILD Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top